Stockreport

Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy

RETROPHIN INC  (RTRX) 
Last retrophin inc earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.retrophin.com/investor-relations
PDF SAN DIEGO, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivot [Read more]